This article reports the results of the Prevention Of Exacerbations with Tiotropium (POET) in COPD study.
This is an original research paper reporting results of the Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) trial.
This secondary manuscript examines the relationship between baseline blood eosinophils and the rate of exacerbation in indacaterol/glycopyrronium versus salmeterol/fluticasone through analysis of FLAME data.
The FLAME trial investigated whether the long-acting β2-agonist indacaterol plus the long-acting muscarinic antagonist glycopyrronium once daily would be at least as effective as the LABA salmeterol plus the inhaled corticosteroid fluticasone twice daily.
The LANTERN study investigated the efficacy and safety of LABA/LAMA bronchodilator indacaterol/glycopyrronium versus twice daily SFC.
The SPARK study evaluated the effects of the once-daily dual LABA/LAMA bronchodilator QVA149 versus the once-daily LAMAs glycopyrronium and tiotropium on exacerbations of COPD.
The ILLUMINATE study investigated the efficacy, safety and tolerability of the once-daily dual LABA/LAMA bronchodilator QVA149 versus the LABA/ICS combination salmeterol–fluticasone.
The Salford Lung Study investigated the effectiveness of a combination of once-daily fluticasone furoate-vilanterol (FF/VI) compared with existing maintenance therapy.
The Study to Understand Mortality and MorbidITy (SUMMIT) investigated whether combination treatment with an ICS and a LABA would improve survival compared with placebo.
TRILOGY investigated whether a fixed-dose combination of beclometasone dipropionate, formoterol fumarate and glycopyrronium bromide would be as effective as BDP/FF in COPD.
The CRYSTAL study investigated the impact of a direct switch to glycopyrronium or indacaterol/glycopyrronium from previous standard-of-care treatments on lung function and dyspnea in symptomatic patients with moderate COPD.
SUNSET was the first randomised controlled trial to investigate the efficacy and safety of direct de-escalation from triple therapy (ICS/LABA+LAMA) to dual bronchodilation (LABA/LAMA) in patients with moderate-to-severe COPD who do not frequently exacerbate.
This study (referred to as WISDOM) investigated the effects of stepwise withdrawal of ICS from triple therapy (ICS + LABA + LAMA) to LABA/LAMA.
The INSTEAD study investigated the efficacy of the once-daily LABA bronchodilator indacaterol compared with the twice-daily LABA/ICS combination of salmeterol/fluticasone.